n803
Recombinant proteinexperimental
Clinical trial activity
38 trials · 24 clinical orgs · 0 marketing orgs
Phase 1
19
Phase 2
28
Phase 3
1
Phase 4
0
Earliest trial started Jan 13, 2018 (NCT03387111)
Timeline
Indications
Studied for
- Acquired Immunodeficiency Syndrome · Phase 1/Phase 2
- Breast Neoplasms · Phase 1/Phase 2
- Carcinoma · Phase 1/Phase 2
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Carcinoma, Merkel Cell · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 3
- Carcinoma, Squamous Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 2
- COVID-19 · Phase 2
- Endometrial Neoplasms · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 2
- Glioblastoma · Phase 2
- Head and Neck Neoplasms · Phase 2
- Healthy Volunteers · Phase 1
- HIV · Phase 2
- HIV Infections · Phase 2
- Hodgkin Disease · Phase 1
- Lymphoma · Phase 1
- Neoplasms · Phase 2
- Neuroblastoma · Phase 2
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Prostatic Neoplasms, Castration-Resistant · Phase 2
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Triple Negative Breast Neoplasms · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 2
Mechanism of action
- Interleukin-15AGONIST
IL15 agonist
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07049432 | Phase 1 | Dec 31, 2025 | ImmunityBio, Inc., University of Utah |
| NCT06829823 | Phase 2 | Nov 30, 2025 | ImmunityBio, Inc. |
| NCT07085338 | Phase 2 | Nov 10, 2025 | St. Jude Children's Hospital |
| NCT07108036 | Phase 2 | Oct 31, 2025 | ImmunityBio, Inc. |
| NCT07145164 | Phase 2 | Sep 1, 2025 | AmFAR, University of California, San Francisco |
| NCT06765954 | Phase 2 | Jun 1, 2025 | ImmunityBio, Inc. |
| NCT06745908 | Phase 3 | Feb 28, 2025 | ImmunityBio, Inc. |
| NCT06765902 | Phase 2 | Jan 31, 2025 | ImmunityBio, Inc. |
| NCT06710288 | Phase 2 | Dec 31, 2024 | ImmunityBio, Inc. |
| NCT06253494 | Phase 1/Phase 2 (Phase 2) | May 14, 2024 | National Cancer Institute (NCI) |
| NCT06061809 | Phase 2 | Feb 29, 2024 | ImmunityBio, Inc. |
| NCT06239220 | Phase 2 | Feb 16, 2024 | Harvard University, ImmunityBio, Inc. |
| NCT06161545 | Phase 2 | Jan 3, 2024 | National Cancer Institute (NCI) |
| NCT06149481 | Phase 1/Phase 2 (Phase 2) | Jan 3, 2024 | National Cancer Institute (NCI) |
| NCT06040918 | Phase 1 | Oct 4, 2023 | ImmunityBio, Inc. |
| NCT05769569 | Phase 1 | Sep 1, 2023 | Chulalongkorn University, Henry M. Jackson Foundation for the Advancement of Military Medicine, Janssen Pharmaceutica NV, United States Army |
| NCT05642195 | Phase 1/Phase 2 (Phase 2) | Dec 29, 2022 | National Cancer Institute (NCI) |
| NCT05445882 | Phase 2 | Dec 29, 2022 | National Cancer Institute (NCI) |
| NCT05245292 | Phase 1 | Dec 15, 2022 | Cornell University, National Institute of Allergy and Infectious Diseases (NIAID), Rockefeller University, University of Pennsylvania |
| NCT05618925 | Phase 1 | Nov 15, 2022 | ImmunityBio, Inc. |
Showing 20 of 38 trials
Page 1 / 2
Organizations
Research & Development (24)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| ImmunityBio, Inc. | For profit | 17 | 13 | 3 | 2020 |
| National Cancer Institute (NCI) | Government | 8 | 8 | 1 | 2020 |
| NantWorks | For profit | 4 | 4 | 1 | 2018 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 3 | 1 | 1 | 2020 |
| Altor Bioscience | For profit | 2 | 1 | 2 | 2018 |
| Cornell University | Academic/Hospital | 2 | 0 | 1 | 2020 |
| Harvard University | Academic/Hospital | 2 | 2 | 2 | 2020 |
| Henry M. Jackson Foundation for the Advancement of Military Medicine | Academic/Hospital | 2 | 1 | 2 | 2020 |
| NantCell, Inc. | For profit | 2 | 0 | 1 | 2018 |
| Rockefeller University | Academic/Hospital | 2 | 1 | 1 | 2020 |
| United States Army | Government | 2 | 0 | 2 | 2020 |
| University of Minnesota | Academic/Hospital | 2 | 2 | 2 | 2019 |
| AmFAR | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2020 |
| Chulalongkorn University | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Eli Lilly | For profit | 1 | 0 | 1 | 2021 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2023 |
| Miltenyi Biotec, Inc. | For profit | 1 | 0 | 1 | 2020 |
| St. Jude Children's Hospital | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Thai Red Cross AIDS Research Centre, Bangkok, Thailand | Academic/Hospital | 1 | 1 | 1 | 2020 |
24 organizations
Page 1 / 2